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Pyridoxal kinase (PL kinase) and pyridoxine 5’-phosphate oxidase (PNP oxidase) 
are the two vitamin B6 salvage enzymes involved in metabolism of the primary inactive 
vitamin B6 (pyridoxal, pyridoxine and pyridoxamine) into the active cofactor form, 
pyridoxal 5’-phosphate (PLP).  PLP, arguably the most important vitamin, is required by 
numerous vitamin B6 (PLP-dependent) enzymes as a co-factor. These enzymes serve vital 
roles in the metabolism of glucose, lipids, amino acids, heme, DNA/RNA and many 
neurotransmitters.  
High levels of vitamin B6 are linked to neurotoxicity, due to the non-specific 
interactions of PLP with non-B6 proteins.
 
This problem is controlled, in part, by 
maintaining a low in vivo concentration of free PLP (~1 μM); raising the intriguing 
question of how the cell regulates, as well as, supplies sufficient PLP to meet the 
requirements of B6 enzymes. Similar to PLP excess, PLP deficiency, due to mutations in 
 xiii 
 
PL kinase and PNP oxidase or drug-induced inhibition of their activity, has been 
implicated in many pathological conditions. 
The objective of this study is to elucidate the mechanisms underlying PLP 
regulation by PL kinase, and its subsequent transfer to dozens of PLP-dependent enzymes. 
A second objective is to gain valuable information into whether a missense mutation 
(S261F) in PL kinase could affect the enzyme activity and/or structure. A third objective is 
to understand how vitamin B6 metabolism by PL kinase is disrupted by the neurotoxic 
compound, ginkgotoxin. 
 The mutant (hPL kinase S261F) was obtained using site-directed mutagenesis. It 
was then expressed, purified and analyzed by circular dichroism, fluorescence 
spectroscopy, enzyme kinetics and native-PAGE. Our results showed no considerable 
differences between wild-type enzyme and the mutant, suggesting the mutation to be non-
pathogenic.  
PLP was found to inhibit PL kinase by binding to the substrate PL site in the 
presence of substrate MgATP to form an abortive ternary complex (PL kinase-PLP-
MgATP). The physiological significance of this ternary complex was also analyzed and it 
was found to be a source of PLP transfer to apo B6 enzymes. 
Enzyme kinetics, affinity chromatography and fluorescence polarization techniques 
were used to test our hypothesis that the reactive PLP is transferred from PL kinase to apo-
B6 enzymes via channeling. Channeling should provide an efficient and protected way for 
PLP transfer from the kinase or oxidase to apo-B6 enzymes. Our results provide a strong 
support to the channeling mechanism.  
 xiv 
 
Ginkgotoxin was found to be a competitive inhibitor of PL kinase with a Ki of 18 
μM. X-ray crystallographic analysis of its binding mode to PL kinase confirmed its binding 
to the substrate PL site of the enzyme.  A unique hydrophobic interaction between its 
lipophilic side chain 4’-OCH3 and nearby Tyr127 and Val231, in addition to the conserved 
PL binding interactions, was found to be responsible for its higher affinity to the enzyme.  
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CHAPTER 1 
GENERAL INTRODUCTION 
 
1.1 B6 vitamers: Vitamin B6 is arguably the most important vitamin. It consists of 
three different 3-hydroxy-2-methyl-pyridine derivatives, including pyridoxal (PL), 
pyridoxine (PN), and pyridoxamine (PM) (Figure 1).  Plants and prokaryotes synthesize these 
B6 vitamers de-novo from small metabolites, but mammalian cells cannot carry out de-novo 
synthesis.
4, 9, 10
 They are mainly dependent upon dietary intake of the vitamins. The non-
phosphorylated B6 vitamers are not biologically active and must be phosphorylated to attain 
activity (Figure 1). Among the phosphorylated derivatives, only pyridoxal 5’-phosphate 
(PLP), and to a lesser extent, pyridoxamine-5’phosphate (PMP) is biologically active.4-7 
 
 
  
 
Figure 1: Structures of the B6 vitamers 
1.2 Vitamin B6 metabolism: The bio-activation of vitamin B6 derivatives is carried out 
by two key enzymes; pyridoxal kinase (PL kinase) and pyridoxine 5’-phosphate oxidase (PNP 
oxidase). Together these enzymes are responsible for PLP synthesis in the salvage pathway, as 
shown in Figure 3. This pathway is active in both prokaryotes and eukaryotes, while de-novo 
pathway for PLP synthesis is only active in prokaryote, in which PLP is synthesized from 
erythrose-4-phosphate by a series of steps, as shown in Figure 2. In the salvage pathway 
2 
 
pyridoxal kinase carry out phosphorylation of all the three forms of vitamin B6, by transferring γ-
phosphate of ATP to 5’–OH group of B6 vitamers; while PNP oxidase is responsible for 
oxidation of PNP and PMP to PLP in both the salvage and de-novo pathways (Figures 2 & 3). 
PLP is recycled during protein turnover via the salvage pathway involving PLP-phosphatase, PL 
kinase and PNP oxidase. Released PLP from proteins is first converted by the phosphatases to 
PL. PNP and PMP in the cells are also converted to PN and PM by phosphatases. These vitamers 
are then acted upon by the oxidase and kinase as described above. Pyridoxal 5’-phosphate (PLP) 
is required as a co-factor by over 140 different vitamin B6 (PLP-dependent) enzymes to carry out 
their biological functions. These enzymes are involved in carrying out several diverse reactions 
including, but not limited to neuro-transmitter catabolism, synthesis of polyamines, methionine 
metabolism, heme biosynthesis, sphingomyelin synthesis, carbohydrate metabolism, nucleic acid 
synthesis and homocysteine metabolism.
1-3
 The metabolism of B6 vitamers can be illustrated 
schematically as shown in Figures 2 and 3; 
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Figure 2: De-novo and Salvage pathways for PLP synthesis; De-novo being active only in 
prokaryotes, while Salvage pathway being active in both prokaryotes and eukaryotes 
 
 
 
 
 
 
 
 
 
Figure 3: Metabolism of B6 vitamers (Salvage pathway) 
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1.3 Pyridoxal kinase: This enzyme is responsible for phosphorylation of B6 vitamers in 
the salvage pathway, in both eukaryotes and prokaryotes. It catalyzes the transfer of γ-phosphate 
from ATP to the 5’-CH2OH of the B6 vitamers, as shown in Figure 4. Most organisms possess 
PL kinase encoded by the gene pdxK, which is highly homologous among prokaryotes and 
eukaryotes.
5
 In addition to the PL kinase coded by the pdxK gene, E. coli and several other 
prokaryotes are also found to contain a homolog PL kinase enzyme (PL kinase 2) coded by the 
gene pdxY. 
4, 5, 9
 PL kinase 2 shares very low sequence identity (~30%) with PL kinase.
5
 This 
protein also functions in salvage pathway but is catalytically very less active as compared to PL 
kinase, therefore its exact role in vitamin B6 metabolism is not clear.
4 
 
 
 
Figure 4: Reaction catalyzed by Pyridoxal kinase 
The PL kinase enzyme follows random sequential addition of substrates.
6
 There are 
several reports about the effects of monovalent and divalent metal cations on the activity of PL 
kinase and for optimal activity, K
+
 and Mg
2+
 are required.
4, 6, 7, 9
 
PL kinases have been purified from several organisms and for many of them crystal 
structures are also known.
5, 6, 9, 46
 All of them show a typical ribokinase superfamily structure of 
core β-sheets surrounded by α-helices (Figure 5A).6 All of them are dimers with active site in 
each subunit (Figure 5B), with conserved ATP and substrate binding geometries. Human enzyme 
5 
 
is more tolerant to changes in substrate chemistries, hence more prone to binding by substrate-
like molecules, including many commonly used drugs.
6, 26
 
A). 
 
 
 
 
 
B). 
 
 
 
 
 
Figure 5: Overall structure of hPL kinase.
6
 (A) The monomeric structure with bound ATP 
(stick), MPD (stick), Na
+
 (brown sphere), and Mg
2+
 (magenta sphere) at the active site. α-Helices 
and β-strands are colored yellow and red, respectively. The secondary structures are labeled. (B) 
The dimeric structure, also with bound ATP (cyan CPK), MPD (gray CPK), Na
+
 (brown sphere), 
and Mg
2+
 (magenta sphere). Monomers A and B are colored red and yellow, respectively. 
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1.4 Pyridoxine 5’-phosphate oxidase (PNP oxidase): PNP oxidase is a flavin 
mononucleotide (FMN) dependent enzyme, which catalyzes oxidation of PNP and PMP to PLP, 
as shown in Figure 6. It is a dimer having FMN bound to each subunit, which acts as an 
immediate electron acceptor, and is regenerated by transfer of the two electrons to oxygen 
forming hydrogen peroxide.
12 
The activity of PNP oxidase is regulated by free PLP in cellular 
environment, since it acts as a product inhibitor of the enzyme activity.
35-38, 40, 41
 
  
 
 
 
Figure 6: Reaction catalyzed by PNP oxidase 
1.5 PLP dependent enzymes: The PLP, after being synthesized by PL kinase and/or 
PNP oxidase, is taken up by apo B6 enzymes. It binds to a specific lysine residue through a 
Schiff base linkage, also called as an internal aldimine, and activates the apo enzyme to the holo 
form, as shown in Figure 7.
14
 These PLP-dependent enzymes carry out diverse reactions such as 
racemization, decarboxylation, β and γ elimination and replacement reactions.14, 16 
Physiologically, these reactions are responsible for neurotransmitter synthesis, heme 
biosynthesis, one carbon unit transfer and hence nucleic acid biosynthesis, sphingomyelin 
synthesis and carbohydrate metabolism.
1
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Figure 7: Activation apo PLP-dependent enzymes to holo enzymes by binding of PLP to 
specific lysine residue at enzyme active site via a Schiff-base linkage 
Since the determination of the first structure of a PLP-dependent enzyme, aspartate 
aminotransferase (AAT), structures of several PLP-dependent enzymes have been determined 
and attempts have also been made to classify these enzymes. Table 1 shows one such 
classification in which the PLP-dependent enzymes were classified into five different subtypes 
according to the similarity in their fold; active site and amino acid sequence.
14-16
   
Table 1: Classification PLP-dependent enzymes with representative examples of each class
 15, 16
 
Family Examples of PLP-dependent enzyme  
Fold type I Aspartate amino transferase (AAT) 
Serine hydroxymethyltransferase (SHMT) 
Glutamate decarboxylase (GAD) 
Fold type II Serine dehydratase 
Cystathionine β-synthase 
Fold type III Ornithine decarboxylase 
Alanine racemase 
Fold type IV Branched-chain amino-acid amino transferase 
Fold type V Glycogen phosphorylase 
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The above classification aptly exemplifies diversity of the PLP-dependent enzymes. It 
also serves to explain the physiological significance of these enzymes, as well as of PLP, which 
is required as a cofactor for their activity. Any alteration in PLP level may adversely affect 
several body functions due to the malfunctioning of PLP-dependent enzymes. 
1.6 Deficiency of PLP: Proper functioning of the PLP-dependent enzymes and thus 
optimal health are dependent upon optimal level of PLP. Pyridoxal 5’-phosphate deficiency has 
been implicated in several neurological and non-neurological disorders, such as induction and 
development of hormone-dependent breast and prostate cancers, convulsions, peripheral nervous 
system damage, impairment of immune response, epilepsy, and autism.
1, 62
 Most dietary sources 
contain vitamin B6, hence PLP deficiency due to dietary insufficiency is less prominent.
1
 Major 
reasons for PLP deficiency can be attributed to malfunctioning of PL kinase and/or PNP oxidase, 
which may be caused either by pathogenic mutations or by drug induced inhibition of these 
enzymes’ activity. 
1.6.1 PLP deficiency due to pathogenic mutations: Several neurological and non-
neurological disorders have been reported due to mutations in the genes coding for PL kinase 
and PNP oxidase.
17, 18, 19, 63, 64
 These mutations may cause impairment of enzymatic activity, low 
protein expressions or disruption of regulation mechanisms which can ultimately lead to PLP 
deficiency.
19
 Mutations in the gene coding for PNP oxidase have been implicated in neonatal 
epileptic encephalopathy (NEE). These mutations resulted in 70-82% reduction in enzymatic 
activity.
17, 19, 20, 64
 Detailed characterization of one such pathogenic mutant (R229W) has been 
carried out in our lab and it was shown that the mutation resulted in decrease in cofactor (FMN), 
as well as substrate (PNP or PMP) binding to PNPO with concomitant decreased in enzymatic 
activity.
19 
Similarly, defective PL kinase has been implicated in children suffering from autism.
19, 
9 
 
64
 Apart from these, the mutations have also been implicated in several other neurological 
disorders including Alzheimer’s disease, Parkinson’s disease, learning disabilities, attention 
deficit hyperactive disorder and anxiety disorders.
19
 Although there is no direct evidence of 
linking each mutation to the disorder but detailed analysis of each mutation may serve in 
designing proper treatment for affected patient.  
1.6.2 PLP deficiency due to drug induced inhibition of PL kinase activity: PL kinase 
inhibiting drugs can be classified into two main classes; first, direct inhibitors of the enzyme 
activity; second, molecules reacting with the B6 vitamers and thereby inhibiting the enzymes.
21
 
First class includes commonly used drugs such as theophylline, enprofylline, roscovitine and 
lamotrigine, while the second class includes drugs such as isoniazid, levodopa, cycloserine and 
D-penicillamine.
21, 25
 Many of the neuro-toxic effects of all the above mentioned drugs can be 
attributed to their inhibitory effects on PL kinase. For theophylline, it is well established that it 
inhibits PL kinase, to which it shows mixed inhibition.
22-24 
The crystal structure of theophylline 
bound to pyridoxal kinase has been deposited to the PDB by our group. Roscovitine, a drug 
currently being tested as a potential anti-cancer agent, is relatively selective for its target (i.e. the 
cyclin dependent kinases), but recently it has been reported to bind to pyridoxal kinase at the 
pyridoxal binding site.
25
 The crystal structure of roscovitine and its derivatives bound to 
pyridoxal kinase indicates the ability of the enzyme active site to accommodate molecules much 
larger than pyridoxal.
26 
Recently, several groups pointed out that the toxic effects of ginkgotoxin 
can be attributed to its inhibitory effects on PLP-synthesizing enzymes. Ginkgotoxin is mainly 
obtained from the seeds and leaves of Ginkgo biloba. Various medications from Ginkgo biloba 
are widely used in the treatment of various conditions ranging from bronchial asthma, irritable 
bladder, depression, dizziness, tinnitus and several others.
27-31
 These medications have prominent 
10 
 
presence in traditional Chinese, Japanese and European system of medicine. In Japan, the seeds, 
also called as “Gin-nan”, are used as food and their consumption has resulted in about 70 food 
poisoning episodes since 1930.
28, 65
 Apart from G. biloba, several Albizzia species also contain 
Ginkgotoxin which is responsible for a condition called “Albizziosis” (Ginkgotoxin poisoning) 
in S. African cattle and sheep.
66
 The symptoms of the toxicity mainly include seizures, 
tonic/chronic convulsions, vomiting and impaired consciousness. The symptoms were found to 
be alleviated by administering PLP.
65
 This indicates that the toxicity can be attributed to the 
inhibition of PL kinase or PNP oxidase, which leads to decrease in PLP levels. The molecular 
mechanism of PLP deficiency by Ginkgotoxin is still needed to be investigated.  
     For all the above mentioned drugs, adverse effects may be alleviated by co-
administering vitamin B6 supplements. Also, knowing the binding mode of these drugs with PL 
kinase may also help in selecting other putative molecules which may bind to PL kinase to elicit 
their adverse effect. These findings will be helpful in improving the pharmacological profiles of 
the corresponding drugs. 
1.7 PLP toxicity: Excess levels of PLP have also been implicated in sensory and 
peripheral neuropathies.
67
 Toxicity of PLP can be attributed to the electrophilic 4’-CHO group 
which can react with several cellular nucleophiles.
67
 Because of this property, PLP is even used 
to label specific amino acids to study proteins.
31 
Several toxicities have been reported due to 
reactivity of PLP. Excess use of vitamin B6 has been implicated in sensory and peripheral 
neuropathies, parethesia, demyelination, and degeneration of sensory neurons in peripheral 
nerves.
67-70
 PLP has been reported to bind GABAA receptors via Schiff base linkage. This 
binding precipitated tonic-clonic convulsions in mice.
32, 33
 In a similar fashion, PLP was also 
found to inhibit the activity of phenol (aryl) sulfotransferase, a major detoxification enzyme.
34
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Thus, the cell requires tight regulation of PLP concentration to reduce its non-specific 
interactions and thus toxicity. Figure 8 summarizes how excess, as well as deficit levels of PLP 
are undesirable, necessitating tight regulation of cellular PLP levels. 
 
 
 
Figure 8: Effects of PLP-deficiency and toxicity 
1.8 Regulation of PLP: Since excess levels of PLP in the cell is undesirable, free PLP 
levels have to be low. Several reports suggest that PLP does not accumulate in any body tissue.
35, 
47 
This raises the basic question of how the concentration of free PLP is regulated in body. 
Several regulatory mechanisms have been proposed and/or identified. These include action of 
PLP specific phosphatase, protein binding and feed-back inhibition of PNP oxidase. Among 
these, PLP specific phosphatase is believed to play very important role.
35, 39, 43 
This enzyme is at 
least 10 fold more active than other phosphatase and it is much more specific for PLP.
39
 This 
enzyme is homologous among all the species examined so far and it is found to be expressed 
ubiquitously in all the tissues with highest expression level in the brain.
39
 This enzyme is 
responsible for dephosphorylation of PLP to the less reactive PL and it requires Mg
2+
 for its 
activity (Figure 9).
39, 67
  
 
 
Figure 9: Reaction catalyzed by PLP-phosphatase 
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     The kcat/Km of 0.6 μM
-1
s
-1
 of this enzyme for PLP, as compared to 0.03 μM-1s-1 of PL 
kinase for PL, explains its high catalytic activity, as well as its importance in PLP homeostasis.
4, 
39
 In addition to the action of PLP-phosphatase, feed-back inhibition of PLP synthesizing 
enzymes is also believed to play a very important role in regulating PLP levels. Previously, it has 
been reported that PLP inhibits PNP oxidase at Ki of 1-25 μM.
35,44
 Induced MgATP substrate 
inhibition of PL kinase in the presence of PLP has also been reported. Our group recently solved 
the crystal structure of PLP bound at the active site of PL kinase along with the substrate 
MgATP, as shown in Figure 10 – (Safo et al., unpublished results). This suggests that PLP forms 
an abortive ternary complex with enzyme PL kinase and substrate MgATP. Binding of PLP at 
active site clearly indicates a possibility of competitive inhibition of enzyme activity by the 
product, PLP. The exact kinetic behavior of PLP inhibition for PL kinase is not known yet.  
 
 
   
 
 
 
 
Figure 10: Crystal Structure of Human PL kinase in complex with bound MgATP and PLP 
at the active site.  
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1.9 Mechanism of PLP transfer: As mentioned in the preceding sections, PLP 
concentration is kept very low (~ 1μM) through several regulatory mechanisms, to reduce its 
toxicity.
35, 47
 Despite this, over 140 apo B6 enzymes manage to obtain enough PLP, which binds 
to a specific lysine residue at the active site of the enzymes and converts them to the fully 
functional holo form, as shown in Figure 7. The question is how they obtain PLP, despite its low 
in vivo concentration. Two possible mechanisms can be proposed, as shown in Figure 11.
35
 
According to mechanism I, synthesized PLP by PL kinase and/or PNP oxidase is first released as 
free PLP in the cytosol, which is then sequestered by apo B6 enzymes. The released PLP is 
susceptible to dephosphorylation by PLP phosphatase to PL and may also react non-specifically 
with several other nucleophiles. The second mechanism (Mechanism II) is a channeling 
mechanism where PL kinase or PNP oxidase forms a complex with an apo B6 enzyme and 
transfers PLP, resulting in activation of apo B6 enzyme to the holo form, without PLP on the 
kinase or oxidase being released into solvent. Substrate channeling has been previously reported 
for several different enzyme systems.
59, 71
 It offers several distinct advantages such as; 
prevention of loss of intermediate by diffusion, protection of labile intermediates from solvent, 
and prevention of entry of intermediates to other metabolic pathways.
58,59
 Previous studies have 
shown that PL kinase can interact with PLP-dependent enzymes like aspartate aminotransferase, 
glutamate decarboxylase, and alanine aminotransferase.
35, 47
 A study by the Schirch group also 
showed that activation of apo B6 enzyme to the holo form in cell extract was more efficient using 
PLP synthesized by PNP oxidase compared to the use of free PLP as shown in Figure 12.
12
 The 
authors suggested that free PLP in the extract was forming non-productive aldimines with cell 
components, e.g. amino acids and proteins. These served to suggest a very strong possibility of 
PLP channeling. 
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Figure 11: Hypothetical mechanisms for transfer of PLP from PLP synthesizing enzymes to 
apo PLP-dependent enzymes 
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Figure 12: Activation of apo eSHMT by PLP and apo PNP oxidase-PLP
12
. (I) Apo eSHMT, 
20 μM, was incubated with 25 μM PLP in 20 mM potassium phosphate, pH 7.3. Aliquots (5 ml) 
were removed every few minutes and assayed for eSHMT activity by observing the increase in 
absorbance at 340 nm/min in a coupled enzymatic assay. (II) Apo eSHMT was incubated under 
the same conditions as described above except the phosphate buffer included 0.3 g/ml of dried 
E. coli cell extract that lacks any SHMT activity. (III) Apo eSHMT, 20 mM, was incubated in 
the E. coli cell extract except the PLP was replaced with 25 μM PNPO-PLP  
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1.10 Rationale and Specific Aim 
Vitamin B6, as PLP, serves as a co-factor in over 140 enzymatic reactions and any 
decrease in PLP level in the cell, either due to mutations in the genes coding for PL kinase and/or 
PNP oxidase or drug induced inhibition of their activity, results in malfunctioning of PLP-
dependent enzymes, which leads to several neurological, as well as, non-neurological disorders. 
The PLP levels, above physiological limit, have also been implicated in several neuropathies. 
Thus tight regulation of PLP concentration is required in the cell. The overall objective of this 
study is to elucidate the mechanisms underlying PLP metabolism and regulation, and its 
subsequent transfer to dozens of PLP-dependent enzymes. Another objective is to gain valuable 
information into how pathogenic mutations in PL kinase as well as inhibition of this enzyme by 
compounds disrupt vitamin B6 metabolism. The study is divided into four specific aims; 
1.  Determine the kinetic regulation of PLP by PL kinase and the mechanism of PLP 
transfer to apo B6 enzymes 
2.  Characterize protein-protein interactions between PL kinase and B6 enzymes 
3.  Determine the effect of PL kinase S261F mutation on PL kinase activity and 
structure 
4.  Determine the effect of ginkgotoxin on PL kinase activity and structure 
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CHAPTER 2 
DETERMINE THE KINETIC REGULATION OF PLP BY PL KINASE AND 
THE MECHANISM OF PLP TRANSFER TO APO B6 ENZYMES 
 
2.1 Introduction: The non-specific interactions of PLP with non B6 proteins, due to high 
chemical reactivity of the aldehyde group on PLP, are controlled in part by maintaining a low in 
vivo concentration (~1 μM) by several regulatory mechanisms. These mechanisms include the 
action of PLP phosphatase and protein binding of PLP.
35, 39, 62, 81
 Feed-back inhibition of PNP 
oxidase activity by PLP also plays an important role.
36-38
 In addition, inhibition of human PL 
kinase activity by the product ADP (Safo et. al. - unpublished results), and the substrate MgATP 
in presence of PLP,
4
 have also been reported. However, unlike the PNP oxidase, there are no 
detailed studies on the regulatory effect of PLP on PL kinase activity.  
The low in vivo concentration of free PLP, as well as its highly reactive nature raises an 
intriguing question of how the cell supplies sufficient PLP, with high specificity, to the dozens of 
B6 enzymes. There are two possible mechanisms for PLP transfer to apo B6 enzymes-via 
channeling of PLP from the kinase or oxidase to the apo B6 enzymes, or via release of the PLP 
from the kinase and oxidase into cytosol as free PLP which then finds its way to the apo B6 
enzymes.  
This chapter focuses on elucidating the effects of PLP on catalytic activity of PL kinase, 
as well as determining the significance of a ternary abortive complex formed between PL kinase, 
MgATP and PLP (referred to as PL kinase-PLP-MgATP). We will also elucidate the mechanism 
involved in the transfer of PLP from PL kinase to activate apo B6 enzyme to the holo form.  
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2.2 Materials: Bacterial culture media ingredients were purchased from Fischer 
Scientific (Pittsburgh, PA) and American Bioanalytical (Natick, MA). All the substrates were 
purchased from Sigma (St. Louis, MO) or Fischer Scientific (Pittsburgh, PA). Sephadex G50 
was purchased from Fischer Scientific (Pittsburgh, PA). DEAE sephadex, ceramic 
hydroxylapatite, and CM sephadex were purchased from Sigma (St. Louis, MO). Nickel 
nitriloacetic acid (NiNTA) was purchased from Qiagen (Valencia, CA). Centrifugal filter devices 
were obtained from Milipore (Bedford, MA). The recombinant plasmid containing the gene 
insert coding for PLP-phosphatase was obtained from the Boe group (Bergen, Norway). 
2.3 Methods 
2.3.1 Expression and purification of human PL kinase (hPL kinase):
 
The
 
human PL 
kinase was purified using the procedure described previously.
5, 11
 Briefly, competent E. coli 
Rosetta (DE3) pLysS cells (Novagen) were transformed with a pET28b vector carrying the 
human pdxK gene insert. Transformants were grown in 6 liters of LB-kanamycin- 
chlroamphenicol (kanamycin 50 μg/mL and chlroamphenicol 34 μg/mL) media and after 
reaching optical density of 0.8 at 600 nm, were induced with 0.5 M mM IPTG. Cells were grown 
for additional 5 hours at 32ºC and harvested by centrifugation. The cell pellets were re-
suspended in 250 ml of 50 mM sodium phosphate buffer, pH 8.0 and rapidly ruptured by high 
pressure homogenization using Avestin cell disrupter. Streptomycin sulfate was added to a final 
concentration of 10 g/L to remove excess nucleic acids. After ammonium sulfate fractionation (at 
30% and 60% saturation), enzyme was dialyzed in 50 mM sodium phosphate buffer, pH 8.0. The 
desalted protein solution was loaded on Ni-NTA column which was equilibrated with 50 mM 
monobasic sodium phosphate, pH 8.0, containing 300 mM NaCl, and 5 mM imidazole. The 
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column was washed thoroughly with equilibration buffer until OD280 was less than 0.1, and 
further washed several times with the same buffer, containing higher concentration of imidazole 
(10-75 mM). The enzyme was eluted from the column with 50 mM monobasic sodium 
phosphate buffer, pH 8.0, containing 300 mM NaCl, and 150 mM imidazole. Fractions 
containing 95% purity, as judged by SDS-PAGE, were pooled and the protein solution was 
concentrated by precipitation with 60% ammonium sulfate. The protein pellets were stored at -
20
°
C for further usage.  
2.3.2 Assay of PL kinase activity: The analysis of activity was carried out in 1cm 
thermostated cuvette in Agilent 8454 spectrophotometer at 37
°
C by recording increase in     
OD388 nm, which indicates PLP formation from PL in presence of MgATP, as shown in Figure 
13.
4 
PL kinase (10-20 μM) was mixed with 1 mM MgATP in 20 mM sodium BES, pH 7 and the 
reaction was started by addition of 150 μM PL. The increase in OD at 388 nm was recorded for 
60 seconds in kinetic mode of the software. 
 
 
 
 
Figure 13: Assaying pyridoxal kinase activity 
 
2.3.3 Expression and purification of E. coli serine hydroxymethyltransferase 
(eSHMT): The eSHMT was purified by a previously reported method, with minor 
modifications.
49 
Briefly,
 
the cDNA of gene glyA, coding for eSHMT, was inserted in vector pGS 
29. The recombinant plasmid was transformed in E. coli K-12 cells. Transformants were grown 
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in 6 L LB-ampicillin (ampicillin 100 μg/mL) media containing 25 mM potassium phosphate (pH 
7.4) and 0.4% glucose, at 37
°
C
 
until they left the log phase of growth, as monitored by OD600nm, 
and harvested by centrifugation. The cells, after re-suspension, were lysed by homogenization at 
high pressure using Avestin cell disruptor. After ammonium sulfate fractionation (50% and 75%), 
protein pellet was dissolved in 20 mM potassium phosphate buffer, pH 7.2 and dialyzed 
extensively against the same buffer containing 0.1 mM PLP and 1mM EDTA. The desalted 
protein was loaded on DEAE-Sephadex column, which was pre-equilibrated with 20 mM 
potassium phosphate buffer, pH 7.2 The column was washed thoroughly with the equilibration 
buffer until OD at 280nm was below 0.2 and then the protein was eluted with linear salt gradient 
of 400 mL equilibration buffer and 400 mL of 50 mM potassium phosphate buffer, pH 6.4 
containing 300 mM NaCl. Spectra of each fraction were recorded using UV-Visible 
spectrophotometer between 250-550nm. The fractions having value of OD280nm/OD423nm ratio 
below 50 were collected and analyzed by SDS-PAGE analysis for purity. Fractions containing 
pure protein were pooled together and protein was precipitated by adding ammonium sulfate to 
75% saturation. The precipitate was dissolved in 20 mM sodium BES buffer, pH 7 and dialyzed 
against the same buffer containing 0.1 mM PLP. The activity of desalted protein was analyzed. It 
was then loaded on hydroxylapatite column, pre-equilibrated with 20 mM sodium BES, pH 7. 
The column was washed thoroughly with equilibration buffer until OD at 280nm was below 0.2 
The protein was eluted with linear gradient of 50 mL equilibration buffer and 50 mL of 100mM 
potassium phosphate buffer, pH 7. The fractions having value of OD280nm/OD423nm ratio below 50 
were collected and analyzed by SDS-PAGE analysis. Fractions of highest purity were pooled 
together. The pooled fractions were finally loaded on TMAE column, from which protein of 
almost 95% purity was obtained. 
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2.3.4 Expression and purification of rabbit cytosolic serine 
hydroxymethyltransferase (rcSHMT):
 
The rcSHMT was expressed and purified by a 
previously reported method.
50 
Briefly, the recombinant plasmid containing the gene insert coding 
for rcSHMT was transformed into E. coli HMS (DE3) cells. Transformants were grown in 6 L 
LB-ampicillin (ampicillin, 100 μg/mL) media containing 0.5% glucose, and buffered with 50 
mM phosphate (pH 7.3), prepared from dibasic potassium phosphate and monobasic sodium 
phosphate. Cells were grown at 37
°
C till OD600nm reached 1.2, induced with 0.5 mM IPTG, 
grown for additional 7 hours and then harvested by centrifugation. Cell pellets were re-
suspended in 20 mM potassium phosphate, pH 7.3 containing 0.1 mM PLP, 5 mM 2-
mercaptoethanol and 0.1 mM EDTA and ruptured by high pressure homogenization using 
Avestin cell disruptor. The protein was then precipitated by adding ammonium sulfate to 55% 
saturation. The precipitate was dissolved in 20 mM potassium phosphate buffer, pH 6.8 and 
dialyzed extensively against the same buffer containing 0.1 mM PLP and 1mM EDTA. This 
desalted protein was loaded on CM-Sephadex column, pre-equilibrated with 20 mM potassium 
phosphate buffer, pH 6.8. The column was washed thoroughly with the equilibration buffer until 
OD at 280nm was below 0.2 Protein was eluted with linear gradient containing 600 mL 
equilibration buffer and 600 mL of 300 mM potassium phosphate buffer, pH 7, containing 5 mM 
2-mercaptoethanol and 0.1 mM EDTA. The spectra of fractions were recorded between 250-500 
nm using UV-visible spectrophotometer. Fractions having OD280nm/OD423nm ratio less than 50 
were collected and analyzed by SDS-PAGE. Fractions containing pure protein were pooled 
together and the protein was precipitated by adding ammonium sulfate to 60% saturation. The 
precipitate was dissolved in 20 mM potassium phosphate buffer, pH 7.3 containing 5 mM 2-
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mercaptoethanol, 0.1 mM EDTA and 0.1 mM PLP. It was dialyzed against the same buffer and 
this desalted protein was analyzed for activity and stored at -20
°
C
 
for further usage.  
2.3.5 Activity analysis of Serine hydroxymethyltransferase: Activity analysis of 
SHMT was carried out by a coupled reactions assay.
49, 50, 56
 In the assay, allothreonine was used 
as a substrate for SHMT and the rate of formation of acetaldehyde was measured by reducing it 
to ethanol by NADH and alcohol dehydrogenase. NADH absorbs at 340nm, but when it gets 
oxidized to NAD
+
 during reduction of produced acetaldehyde to ethanol, gradual decrease in 
OD340nm is observed. Therefore the activity of SHMT was monitored by recording change in 
OD340nm in 1 cm thermostated cuvette at 30
°
C
 
using Agilent 8454 spectrophotometer. About 10 
μg SHMT was mixed with 90 μg alcohol dehydrogenase and 180 μg NADH in 50 mM sodium 
BES buffer, pH 7.3 The reaction was started by addition of 10 μM allothreonine and decrease in 
OD at 340 nm was followed for 60 seconds.  
2.3.6 Expression and purification of human PLP-phosphatase: The human PLP-
phosphatase was purified by a previously reported procedure with minor modifications.
39
 The 
recombinant plasmid containing the gene insert, coding for PLP-phosphatase, was transformed to 
E. coli HMS (DE3) pLys cells. The transformants were grown in 6 L LB-ampicillin media 
(ampicillin 100μg/mL). Cells were grown at 37°C  until OD600nm reached 0.6, induced with 50 
μM β-isopropylthiogalactopyranoside (IPTG), grown for additional 24 hours at 18°C  and then 
harvested by centrifugation. The cell pellets, after re-suspension, were lysed by high-pressure 
homogenization using Avestin cell disruptor. Streptomycin sulfate was added to the cell lysate at 
final concentration of 10g/L to remove excess nucleic acids. After centrifugation, the lysate was 
loaded on NiNTA column, pre-equilibrated with 50 mM monobasic sodium phosphate, pH 8.0, 
containing 300 mM NaCl, and 5 mM imidazole. The column was washed thoroughly with 
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equilibration buffer until the OD280 was less than 0.1, and further washed several times with the 
same buffer, containing higher concentration of imidazole (10-75 mM). The enzyme was eluted 
from the column with 50 mM monobasic sodium phosphate buffer, pH 8.0, containing 300 mM 
NaCl, and 150 mM imidazole. Fractions containing 95% purity, as judged by SDS-PAGE, were 
pooled and the protein solution was concentrated by precipitation with 60% ammonium sulfate. 
The precipitate was dissolved in 0 mM sodium BES buffer, pH 7 containing 4 mM MgCl2 and 
dialyzed against the same buffer. It was stored at -20
°
C for further usage. 
 2.3.7 Activity analysis of PLP-phosphatase: The analysis of PLP-phosphatase activity 
was carried out in 1cm thermostated cuvette in Agilent 8454 spectrophotometer at 37
°
C by 
recording a decrease in OD388 nm, which indicates dephosphorylation of PLP to PL, as shown in 
Figure 14.
39, 43
 PLP-phosphatase was taken in 20 mM sodium BES buffer, pH 7 containing 4 mM 
MgCl2. The reaction was started by addition of the substrate PLP at concentration of 100 μM and 
decrease in OD at 388 nm was recorded for 60 seconds.  
 
 
 
 
   
Figure 14: Assay of PLP-phosphatase activity 
2.3.8 Preparation of ePL kinase-PLP-MgATP ternary abortive complex: PL kinase 
(300 μM) was mixed with its substrates, pyridoxal (PL, 400 μM) and MgATP (1 mM) in 20 mM 
sodium BES, pH 7 and incubated at 37
°
C for 1 hour. This reaction mixture was passed through 
Sephadex G50 column (0.6 x 45 cms), pre-equilibrated with 20 mM sodium BES, pH 7 
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containing 1 mM MgATP. About 400 μL fractions were collected and analyzed for eluted 
protein and PLP, by recording optical density at 280nm and 388nm respectively. Fractions 
containing high concentration of protein were pooled together and stored in 500 μL aliquots at    
-20
°
C for further use. 
2.3.9 Preparation of apo serine hydroxymethyltransferase: Apo enzyme was prepared 
according to the method previously reported.
49 
Briefly, holo SHMT (eSHMT or rcSHMT, 500 
μL) was mixed with EDTA (1 μM), dithiothreitol (DTT, 1 μM), D-alanine (200 μM) and 
ammonium sulfate (200 μM) in 50 mM potassium phosphate buffer, pH 7. The reaction mixture 
was incubated at 37
°
C with shaking at 150-180 rpm until the yellow color disappeared. It was 
dialyzed extensively against 50 mM potassium phosphate, pH 7.4 containing 0.5 mM EDTA and 
1mM DTT. The apo enzyme was quantified by measuring protein absorbance at 280 nm. It was 
then stored in 500 μL aliquots, containing 10% glycerol, at -70°C. 
2.3.10 Determination of stoichiometry of PLP binding to ePL kinase-PLP-MgATP 
complex: The stoichiometry of PLP binding was analyzed by two different methods. In the first 
method, ePL kinase-PLP-MgATP (100 μL, 10-15 μM) was diluted to 900 μL and OD280nm was 
measured to quantify protein. To this, NaOH solution was added to a final concentration of 0.1 N 
and OD388nm was recorded. The released PLP was quantified using molar extinction co-efficient 
of 6600 M
-1
cm
-1
. In the second method, PLP was used to activate apo SHMT to holo SHMT. 
This holo SHMT ultimately forms a ternary quinonoid complex with glycine and 
tetrahydrofolate (THF) having absorption maximum at OD491nm. First, known concentrations of 
PLP (5-25 μM) were added to the reaction mixture of apo SHMT (20 μM), glycine (50 mM) and 
THF (100 μM). Formation of the quinonoid complex was followed for 15 minutes and 
∆OD491nm/15min values obtained for different concentrations of added PLP were used to plot a 
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standard curve of ∆OD491nm versus PLP concentration. From the ePL kinase-PLP-MgATP 
complex, PLP was first released by adding it to 0.1 N NaOH solution. The complex was added to 
a final concentration of 10-15 μM. This mixture was then added to 350 μL of 100 mM sodium 
BES buffer, pH 6.5 to bring pH at 6.5. To this mixture; apo SHMT, glycine and THF were added 
to final concentrations of 20 μM, 50 mM and 100 μM respectively. The reaction was followed 
for 15 minutes and the ∆OD491nm/15min value was recorded, which was further used to 
extrapolate the amount of PLP released from the standard curve. This amount of PLP was 
compared with the protein concentration to find out the stoichiometry of PLP binding. 
2.3.11 Kinetic analysis of inhibition of PLP on PL kinase activity: The assay for PL 
kinase activity was carried out in 20 mM sodium BES buffer, pH 7 containing 2 mM MgCl2 at 
37°C using Agilent 8454 spectrophotometer as described previously under section 2.3.2. 
Substrates PL and MgATP were used at concentrations of 150 μM and 1 mM respectively, while 
PL kinase was used at concentration of 10 μM. Concentration of PLP was varied between          
1-500 μM to analyze its effects on PL kinase activity. Initial velocity data were recorded and    
“% enzyme activity” was calculated. It was plotted against PLP concentration and fitted in 
Sigmaplot-11. An approximate Ki value for PLP inhibition was determined by using Cheng-
Prusoff equation
42
 (Equation 1), in which PL was considered as a substrate to which PLP acted 
as a competitive inhibitor. 
   
    
  
   
  
        
where, [S] = concentration of PL, 150 μM 
           Km = 30 μM for PL 
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2.3.12 Test of compartmentation or channeling of PLP from ePL kinase to apo 
SHMT: The transfer of PLP from PL kinase to apo SHMT was followed by a coupled assay, in 
which the PLP synthesized by PL kinase was used to convert apo SHMT to holo form. This holo 
SHMT formed a ternary quinonoid complex absorbing at 491 nm. The enzymes                      
ePL kinase (20 μM), apo eSHMT (20 μM) and PLP-phosphatase (3 μM) were mixed together 
with glycine (50 mM), tetrahydrofolate (100 μM) and MgATP (1 mM) in 20 mM sodium BES 
buffer pH 7. The reaction was started by addition of PL (20 μM) and increase in OD491nm was 
followed for 15 minutes.  
Controls were run in parallel. First control contained apo SHMT and PL kinase with all 
the substrates, but PLP-phosphatase was omitted. Second control contained free PLP, and       
apo SHMT with its substrates, but PL kinase and its substrates MgATP and PL were omitted. In 
this case, the reaction was started by addition of PLP to the enzyme mixture. Third control 
contained free PLP and apo SHMT with its substrates, but PL kinase, its substrates and PLP-
phosphatase were omitted. 
Similar experiments were run to analyze the transfer of tightly bound PLP from ePL 
kinase-PLP-MgATP to apo SHMT. For this, the enzymes apo SHMT (20 μM) and PLP-
phosphatase (3 μM) were mixed with glycine (50 mM) and tetrahydrofolate (100 μM) in 20 mM 
sodium BES buffer, pH 7 containing 1 mM MgATP. Reaction was started by addition of tightly 
bound PLP (20 μM) in form of ePL kinase-PLP-MgATP complex and OD491nm was followed for 
15 minutes. Activation of apo SHMT by free PLP, in presence and in absence of PLP-
phosphatase, was also followed as control. In another control, activation of apo SHMT was 
followed by addition of tightly bound PLP in form of ePL kinase-PLP-MgATP without the 
addition of PLP-phosphatase. 
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Figure 15: Scheme for following transfer of PLP from PL kinase to apo SHMT 
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2.4 Results and Discussion: 
2.4.1 Purity of the enzymes: All the enzymes were >90% pure as judged by SDS-PAGE 
analysis. Figure 16 shows the pictures of gels after the final column in the purification of each 
enzyme; 
                        A) 
 
 
 
 
 
 
 
 B)                                                                                                 C)                  
 
 
 
 
 
 
 
 
Figure 16: SDS-PAGE analysis of the fractions eluted out from the final column for 
purification of A) hPL kinase, B) eSHMT C) rcSHMT 
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     2.4.2 Binding of PLP to PL kinase as a ternary complex with substrate MgATP 
(PL kinase-PLP-MgATP): PNP oxidase purified from brain and liver tissues was found to be 
inhibited by the product PLP at Ki ranging from 1-25 μM.
37, 38, 41, 44
 Choi and Churchich  reported 
that PLP in 10-fold excess inhibits sheep brain PNP oxidase significantly, and the inhibition was 
due to binding of PLP via aldimine linkage to a specific lysyl residue on protein.
36
 Similarly, E. 
coli PNP oxidase was also found to be inhibited by PLP.
40
 The characterization of PLP binding 
to E. coli PNP oxidase has also been carried out and PLP was found to bind tightly at a non-
catalytic site of the enzyme.
12
 This tightly bound PLP was found to be a very good source to 
activate apo SHMT in the cell extract, as compared to free PLP.
12 
These observations suggest 
that PLP, in addition to exerting product inhibition on PNP oxidase, may bind to the enzyme at 
non-catalytic site, which may serve as a control mechanism for PLP regulation. PLP binding to 
human PL kinase has also been reported and the crystal structure of human PL kinase complexed 
to PLP and MgATP has been deposited to Protein Data Bank [PDB id 3KEU]. This crystal 
structure of PL kinase-PLP-MgATP shows PLP to bind at the active site of the enzyme at the PL 
site. In PL kinase structures, the 5’-OH group of the substrate PL is situated 6-7 Å away from the 
γ-phosphate of ATP, which provides room for co-existence of the 5’-phosphate of the product 
PLP and the substrate ATP together. The bound PLP remains anchored to the active site with the 
help of numerous interactions with amino acid side-chains and an additional Mg
2+
,
 
as shown in 
Figure 10. The crystal structure of PL kinase-PLP-MgATP gave an important insight into the 
binding mode of PLP. We have conducted studies to further characterize this ternary complex 
and also elucidate its possible inhibitory effect on PL kinase activity. The ePL kinase-PLP-
MgATP complex was prepared by incubating the enzyme ePL kinase with substrates PL and 
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MgATP for an hour. The reaction mixture was then loaded on Sephadex G50 column. The 
elution profile is shown in Figure 17. 
 
 
 
 
 
 
 
Figure 17: Elution profile of ePL kinase incubated with PL and MgATP after passing 
through Sephadex G50 (0.6 x 45 cms). 
     The elution profile shows peaks of protein (280 nm) and PLP (388 nm). The 
coincident rise of 388nm peak along with the protein peak clearly indicates the binding of PLP to 
PL kinase which absorbs at 388 nm. Apart from this, free PLP was separated effectively as seen 
from the elution profile. Most interestingly, and also observed previously for the tightly bound 
PLP on PNP oxidase, the bound PLP on PL kinase could not be separated from the protein by 
dialysis or even after passing it second time through the same column. This indicates the fact that 
PLP remains tightly bound to PL kinase. 
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2.4.3 Determination of stoichiometry of PLP binding: The stoichiometric binding of 
PLP to PL kinase was analyzed by two different methods. In each of these methods, bound PLP 
was first released by adding 0.1 N NaOH, which served to denature the protein and thus the 
release of bound PLP. In the first method, the amount of PLP released was determined by 
recording OD388nm and using molar absorption co-efficient of 6600 M
-1
cm
-1
 for PLP.
12
 Figure 
18A shows the spectra of PLP, before and after the addition of 0.1N NaOH. In the second 
method, the released PLP, after neutralizing the solution, was used to activate apo SHMT which 
subsequently formed ternary quinonoid complex with glycine and tetrahydrofolate (THF), 
absorbing strongly at 491nm. It has molar extinction co-efficient of 20000 M
-1
cm
-1
.
 12, 52, 53
A 
standard curve for formation of the quinonoid complex was plotted against the concentration of 
PLP used. The PLP released from ePL kinase-PLP-MgATP was quantified from this standard 
plot and compared to the protein concentration to determine the stoichiometry. Figure 18B shows 
the standard plot of ∆OD491nm versus different PLP concentrations, from which PLP released 
from PL kinase-PLP-MgATP complex was quantified. Table 2 summarizes the results obtained 
by both methods and it indicates that one molecule of PLP binds to each subunit of PL kinase in 
1:1 fashion. 
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Figure 18: Determination of stoichiometry of PLP binding to ePL kinase-PLP-MgATP 
ternary abortive complex; A) Stoichiometry determination by OD388nm method; blue curve 
shows spectra of the complex before addition of 0.1 N NaOH, while red curve is spectra of the 
complex after adding 0.1N NaOH, B) Stoichiometry determination using OD491nm method 
 
Table 2: Determination of stoichiometry of PLP binding to ePL kinase-PLP-MgATP complex 
 OD388nm method OD491nm method 
Stoichiometry (Protein:PLP) 1.01 1.07 
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2.4.4 Inhibition of PL kinase activity by product PLP: The effect of PLP on the 
catalytic activity of PL kinase was analyzed spectrophotometrically. Figure 19 shows the profile 
for PLP inhibition of PL kinase activity. The IC50 and Ki for this inhibition by PLP are indicated 
in Table 3 
 
 
 
 
  
 
 
 
 
 
  
Figure 19: Inhibition of catalytic activity of PL kinase by product PLP; 10 μM PL kinase 
was checked for activity by converting 150 μM of PL to PLP by the transfer of γ-phosphate from 
MgATP (1 mM) in presence of PLP (1-500 μM) 
 
 
Table 3: Kinetic parameters for inhibition of PL kinase activity by PLP 
 
IC50 135.9 ± 0.6 μM 
Ki 22.7 ± 0.1 μM 
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The obtained Ki for PLP inhibition of PL kinase activity is comparable to Ki of 23 μM for 
PNP oxidase inhibition, reported by Churchich et. al.
44
 This suggests that PLP may also be 
serving as a control factor in PL kinase activity, which acts in concert with other regulatory 
mechanisms to prevent the accumulation of highly reactive PLP in cellular environment.  
The obtained Ki is still higher than the average concentration of free PLP found in 
cellular environment, but an explanation can be given for this. There are several reports of 
formation of protein-protein complexes between PL kinase and PNP oxidase, as well as, the 
complexes between PL kinase and other PLP-dependent enzymes like aspartate 
aminotransferase, alanine aminotransferase and glutamate decarboxylase.
35, 44, 47
 This can be 
generalized for all the other PLP-dependent enzymes also, as described in following chapters. 
The formation of protein aggregates like these prevent the diffusion of PLP, which increases the 
local concentration of PLP to several-fold as compared to the cellular PLP levels. Keeping these 
facts in mind, it can be proposed that physiologically, PLP may self-regulate its intra-cellular 
levels by inhibition of the salvage enzymes, PL kinase and PNP oxidase. 
2.4.5 Transfer of PLP from PL kinase to apo SHMT: We studied activation of apo B6 
enzyme using PLP produced during steady state catalytic activity of PL kinase from the 
substrates PL and MgATP. In a previous study Churchich et al.
35
 showed that PL kinase and 
AAT interacted together prior to PLP transfer.  They checked the possibility of PLP channeling 
by including a trapping agent (alkaline phosphates), and the results showed that the phosphatase 
did not have any effect on the rate of transfer, suggesting a possibility of channeling. Alkaline 
phosphatase, used in their studies, is relatively non-specific and has broad substrate specificity.
39 
We conducted similar experiments with apo SHMT, and also used PLP-phosphatase instead of 
alkaline phosphatase as a trapping agent.   
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We analyzed the transfer of PLP by mixing ePL kinase, apo eSHMT and PLP-
phosphatase together with MgATP, glycine and THF. The assay scheme is shown in Figure 15. 
The reaction was started by adding PL, which was converted to PLP by PL kinase and then 
incorporated into apo eSHMT to activate it. Control in the absence of PLP-phosphatase was also 
run. Another control using free PLP in the presence and absence of PLP-phosphatase were also 
conducted. Figure 20 shows the result of this experiment; 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 20: Test of compartmentation or channeling of PLP from ePL kinase to apo 
eSHMT; activation of apo SHMT by free PLP in absence (blue curve), and in presence of PLP-
phosphatase (red curve). Activation of apo SHMT by PLP produced during steady state catalytic 
activity of ePL Kinase, in absence (purple curve), and in presence of PLP-phosphatase (Green 
curve) 
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From Figure 20, it is evident that PLP, after being synthesized by ePL kinase was 
efficiently transferred to apo eSHMT despite the presence of PLP-phosphatase (green curve), 
although there seems to be some slight effect by the phosphatase. Nevertheless, when free PLP 
was used to activate apo eSHMT, no activation was observed (red curve). In absence of PLP-
phosphatase, activation either by free PLP (blue curve) or by PLP synthesized by ePL kinase in 
the reaction mixture is almost similar (purple curve). This trapping experiment, although does 
not conclusively prove channeling, but definitely proves that free PLP was not involved in the 
transfer. For channeling to occur; both proteins, ePL kinase and eSHMT, should associate to 
form a protein-protein complex. The study to characterize this complex formation is discussed in 
chapter 3.  
2.4.6 Transfer of tightly bound PLP on ePL kinase (ePL kinase-PLP-MgATP 
complex) to apo SHMT: We have shown above that PLP binds tightly at the active-site of PL 
kinase. The PLP remains bound even after dialysis or even passing it through the sizing column. 
To determine if the tightly bound PLP can be transferred to apo B6 enzyme and the mode of 
transfer, we followed the activation of both E. coli and rabbit apo SHMT with E. coli PL kinase-
PLP-MgATP complex in the presence and absence of PLP-phosphatase. Controls were run by 
following activation of apo eSHMT and rcSHMT with free PLP, in absence and presence of 
PLP-phosphatase. Figures 21 and 22 shows the result of the experiment; 
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Figure 21: Activation of apo eSHMT by PLP (free and tightly bound); activation of apo 
eSHMT by free PLP, in absence (blue curve) and in presence of PLP-phosphatase (purple curve). 
Activation of apo enzyme by tightly bound PLP on ePL kinase-PLP-MgATP complex in 
presence (red line) and in absence of PLP-phosphatase (green curve) 
Figure 22: Activation of apo rcSHMT by PLP (free and tightly bound); Activation of apo 
rcSHMT by tightly bound PLP from ePL kinase-PLP-MgATP in absence (blue curve) and in 
presence of PLP- phosphatase (green curve). Activation of apo rcSHMT by free PLP in absence 
(red curve) and in presence of PLP- phosphatase (purple curve)   
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The results, as shown in Figure 21, suggest that the tightly bound PLP, which did not 
separate from ePL kinase-PLP-MgATP complex by dialysis and passage through sizing column, 
was easily transferred to apo eSHMT to activate the enzyme (red curve). This transfer was found 
to be almost not affected by action of PLP-phosphatase (green curve), while free PLP was 
completely inhibited from activating the apo B6 enzyme in the presence of the phosphates 
(purple curve). We observed similar results when rabbit cytosolic serine 
hydroxymethyltransferase (rcSHMT) was used instead of eSHMT (Figure 22).  This study shows 
that the ternary complex may be a source of PLP for activation of apo B6 enzyme, and also the 
result gives additional support to the channeling mechanism. The results were also consistent 
with the observation by Yang and Schirch
12
 that PNP oxidase-PLP is a better source of PLP for 
apo SHMT activation as compared to free PLP in cell extract.  
 Although the concentrations of free PLP and PLP on PL kinase-PLP-MgATP are the 
same, the rate of activation by free PLP is about twice that of the complex.  This is in contrast to 
the transfer study using steady state production of PLP. At present we do not have any 
explanation, but it could be that PL kinase-PLP-MgATP forms a non-dissociating complex with 
B6 enzymes and, which may hinder PLP channeling to all available sites on B6 enzymes. In 
effect there is only a half-site transfer. Consistently, if free PLP is added to this complex after 
700 sec (see Fig. 21 & 22), we observe fully activated SHMT.  
2.4.7 Transfer of tightly bound PLP on ePL kinase (ePL kinase-PLP-MgATP 
complex) to apo SHMT in absence of MgATP: We have shown that MgATP is important in 
forming the ternary PL kinase-PLP-MgATP complex. The X-ray structure shows intimate 
interaction between the phosphate of the ATP and phosphate of the PLP mediated by Mg
2+
 ion. 
The above transfer study with ePL kinase-PLP-MgATP involves the use of additional MgATP (1 
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mM) in the reaction buffer to keep the enzyme in the abortive form. To test whether we will 
observe similar apo B6 activation profile without extra MgATP, we repeated the above 
experiment without extra MgATP. The result is shown in Figure 23, and it indicates that in the 
presence of PLP-phosphatase the activation of apo eSHMT was found to be lower (green curve), 
as compared to the control in which PLP-phosphatase was omitted (red curve). This is in contrast 
to the previous experiment with extra MgATP that showed presence and absence of phosphatase 
resulted in similar activation. This suggests the importance of Mg
2+
 in stabilizing the binding of 
both ATP and PLP at the active site.  
 
 
 
 
 
 
 
 
Figure 23: Activation of apo eSHMT by PLP in absence of 1mM MgATP; Activation of apo 
eSHMT by tightly bound PLP from ePL kinase-PLP-MgATP complex in absence (red line), and 
in presence of PLP-phosphatase (green curve). Activation of apo eSHMT by free PLP in absence 
(blue line), and in presence of PLP-phosphatase (purple line) 
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2.5 Conclusion: Cellular level of free PLP is regulated by combination of different 
mechanisms including activity of PLP-phosphatase and feed-back inhibition of PNP oxidase. 
This study also suggests feedback inhibition of PL kinase as another possible mechanism of PLP 
regulation.  PLP inhibits PL kinase by binding to the active site and forming a non-productive 
ternary complex PL kinase-PLP-MgATP at Ki of 22.6 μM. Spectrophotometric and structural 
data showed that one molecule of PLP binds at the active site of the enzyme at each subunit. It 
remains tightly bound to the enzyme even after dialysis or after passing through a sizing column. 
The transfer studies also suggest strong possibility of channeling of PLP from PL kinase to PLP-
dependent enzyme. 
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CHAPTER 3 
CHARACTERIZE PROTEIN-PROTEIN INTERACTIONS BETWEEN PL KINASE 
AND B6 ENZYMES 
 
3.1 Introduction: 
The experiments described in previous chapters suggest channeling or compartmentation 
to be a probable mechanism for PLP transfer from PL kinase to PLP-dependent enzymes. 
Nevertheless, conclusive proof for channeling mechanism requires that a physical complex forms 
between the kinase and B6 enzymes. Association of proteins into supermolecules for transfer of 
substrates has been recognized for several years. Several biophysical and molecular biology 
methods are available to detect and quantify protein-protein interactions. These include but not 
limited to affinity chromatography, affinity blotting, immunoblotting, co-immunoprecipitation, 
fluorescence polarization (FP), and Surface Plasmon Resonance (SPR).
57 
In our studies we used 
affinity chromatography and FP to determine whether PL kinase makes specific interaction with 
various B6 enzymes, a pre-requisite for channeling mechanism. 
Affinity chromatography, which provides qualitative measure of the interaction, employs 
a very simple approach to detect protein-protein interactions. It involves attachment of one of the 
interacting partner on solid support, from which non-specific proteins are readily washed off by 
buffer containing low salt concentration. The attachment can be done by using one of several 
approaches, such as affinity tagging, epitope tagging or employing fusion proteins. After 
immobilizing one of the interacting partners on solid support, the other partner or cell lysate is 
added on it. This added protein or any protein in the cell lysate, if interacts with the immobilized 
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protein, will also be immobilized on the solid support, while other non-specific proteins get 
washed off. The interacted proteins are co-eluted and analyzed to confirm the interaction.  
Fluorescence polarization is a very sensitive technique for the quantification of protein-
protein or protein-ligand interactions.
57, 60 
The phenomenon of fluorescence polarization depends 
upon the rotational movement of fluorescent molecule. Any fluorescent molecule, having an 
absorption dipole parallel to the plane polarized light become excited by plane polarized light at 
its excitation wavelength. It remains in the excited state for certain time (termed fluorescent life-
time, and ranges between one to ten nanoseconds) and return to ground-state while emitting 
light. During fluorescent life time, the excited molecule is prone to rotational movement, which 
decreases the chances of emitting the light parallel to the absorption dipole and thus results in 
relative depolarization of fluorescence intensity. The rotational movement, in turn, depends upon 
the molecular mass of the fluorescent molecule. Increase in molecular mass results in increase in 
polarization due to decrease in rotational movement during fluorescent life-time. This property 
makes this technique very useful in quantifying the protein-protein interactions, in which one of 
the interacting partners is fluorescently tagged. The availability of different fluorescent dyes, 
with fluorescence life-times ranging from one to ten nanoseconds, makes fluorescence 
polarization a very sensitive technique for quantifying protein-protein interactions for proteins 
between ten to hundreds of kilodaltons.
60
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3.2 Materials: Nickel nitriloaceticacid (NiNTA) slurry was purchased from QIAGEN 
(Valencia, CA). Fluorescein-5-maleimide was purchased from Invitrogen (Eugene, OR). The 
Corning 96-well plates (model 3792) were purchased from Sigma Aldrich (St. Louis, MO). 
Glycogen phosphorylase b was purchased from Sigma Aldrich (St. Louis , MO). All the proteins 
were purified as described previously. Centrifugal filter devices were obtained from Milipore 
(Bedford, MA).  
3.3 Methods 
3.3.1 Preparation of enzyme solutions: Purity of all the proteins was judged by SDS 
PAGE. All the proteins were concentrated using Centricon-YM 30 filter devices (MWCO 30 
kDa) and dialyzed against 20 mM Sodium BES, pH 7 for use in affinity chromatography 
experiment, while for fluorescence polarization, they were dialyzed against 50 mM HEPES 
buffer, pH 7.55 containing 150 mM KCl and 0.01% Triton. The proteins were quantified by 
recording OD280nm using their extinction co-efficient as previously reported.
4, 55, 73
  
3.3.2 Activity analyses of purified enzymes: All the purified enzymes were analyzed for 
their activity as per the procedures described in previous chapter.  
3.3.3 Characterization of protein-protein interactions using affinity 
chromatography: The two proteins were mixed in 1:1 stoichiometry. 1 mg of protein mixture 
was taken and diluted to 100 μL with 20 mM sodium BES buffer, pH 7. This protein mixture 
was loaded on NiNTA column, pre-equilibrated with 50 mM monobasic sodium phosphate, pH 8 
containing 300 mM NaCl and 5 mM imidazole. The bed volume of column was 500 μL. After 
loading the mixture, the column was washed thoroughly with the equilibration buffer (washing 
buffer). Fractions of 400 μL were collected and analyzed for protein content by recording 
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OD280nm. The column was washed till no protein came out, as observed from OD280nm. After 
washing, bound protein was eluted by 50 mM monobasic sodium phosphate, pH 8 containing 
250 mM imidazole and 300 mM NaCl (elution buffer). Protein elution was monitored by 
recording OD280nm. Control experiments were also run, in which individual proteins, i.e. hPL 
kinase and rcSHMT were loaded on NiNTA column. Fractions for washing and elution were 
collected in similar fashion. Finally, the fractions for washing and elution for hPL kinase, 
rcSHMT and hPL kinase + rcSHMT were analyzed by SDS-PAGE.  
 3.3.4 Preparation of labeled PL kinase with Fluorescein-5-maleimide: For 
quantification of the protein-protein interactions, we used fluorescence polarization technique, 
and this section describes the tagging of PL kinase with fluorescein-5-maleimide for this study. 
Fluorescein-5-maleimide tags the protein via reacting with the –SH present on proteins. For 
tagging PL kinase, fluorescein-5-maleimide (1 mM) was mixed with 50 μM PL kinase in 1 mL 
of 50 mM sodium HEPES buffer, pH 7.55 containing 150 mM KCl and 0.01% Triton. The 
reaction was allowed to proceed overnight at 4
°
C in the dark. The reaction mixture was then 
centrifuged to remove any precipitate. The supernatant was dialyzed extensively against the 
same buffer in dark. The degree of labelling was determined by using equation 2. Catalytic 
activity of the protein was assessed before and after labelling by the assay described in chapter 2, 
section 2.2.3, to determine if labelling interferes with the activity of ePL kinase.  
                            
                            
                            
                     
Amax is A495 and ε’ is the molar extinction coefficient of FMI, which is 68,000 M
-1
 cm
-1
.  
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3.3.5 Quantification of protein-protein interactions using fluorescence polarization 
(FP): Corning 96-well plates (model 3792) were used to carry out the FP measurements to 
quantify the interactions between ePL kinase and the following B6 enzymes, E. coli L-threonine 
aldolase (eL-TA), E. coli aspartate aminotransferase (eAAT), E. coli serine 
hydroxymethyltransferase (eSHMT), rabbit cytosolic serine hydroxymethyltransferase 
(rcSHMT) and glycogen phosphorylase b (GlyPb) from rabbit muscle. The tagged PL kinase (1 
μM) was titrated with increasing concentrations of the B6 enzymes mentioned above. The 
concentrations of PLP-dependent enzymes were varied from 1μM to 50 μM. Polarization 
measurements were conducted using Tecan Polarion polarimeter. The excitation wavelength and 
emission wavelengths were set at 495 nm and 535 nm respectively. The polarization values (in 
mP) were directly read from Microsoft Excel spreadsheet interfaced with the polarimeter. These 
obtained polarization values were plotted against concentrations of PLP-dependent enzymes. The 
dissociation constants for the protein-protein complexes were obtained by fitting the curves to 
equation 3 using Sigmaplot 11; 
     
                 
          
        
Where, Pobs is the observed polarization value, P0 is the polarization value when no PLP-
dependent enzyme was added, Pmax is the maximum polarization value obtained upon saturation 
of the polarization curve , Kd is the dissociation constant for the protein-protein complex and [E] 
is the concentration of PLP-dependent enzymes. 
The above equation was derived from the equation 4
61
 by assuming the equilibrium;   
FMI-PLK + E              FMI-PLK -E; where FMI-PLK is the tagged PL kinase with FMI 
(fluorescein-5-maleimide) and E is the PLP-dependent enzyme. 
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where, Pobs is the observed polarization values, PFMI-PLK  is polarization intensity of 
tagged PL kinase, PFMI-PLK-E is the polarization values of the complex of tagged PL kinase and  
PLP- dependent enzyme, when all the PL kinase is in the complexed form. [FMI-PLK] and          
[FMI-PLK-E] are the concentrations of uncomplexed and complexed tagged-PL kinase 
respectively. 
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3.4 Results and Discussion: 
3.4.1 Affinity chromatography for detection of protein-protein interactions: In our 
study, human PL kinase, with 6x-His tag on the N-terminal, provided a very easy way to 
immobilize it on NiNTA column. In this experiment, rcSHMT was not His-tagged, nevertheless 
if interaction occurs between hPL kinase and rcSHMT, it should result in immobilization of 
SHMT along with the PL kinase. The possible interaction between hPL kinase and rcSHMT was 
analyzed by loading 1:1 stoichiometric mixture of both enzymes on NiNTA column. Figure 24 
shows the result of SDS-PAGE analysis of fractions obtained after washing (5 mM-30 mM) and 
elution (150 mM-250 mM) of NiNTA column loaded with hPL kinase alone (control), rcSHMT 
alone (control) and 1:1 stoichiometric mixture of hPL kinase and rcSHMT on the NiNTA 
column. Table 4 describes the results of the experiment.  
 
 
 
 
 
 
 
 
 
Figure 24: SDS-PAGE analysis of affinity chromatography eluates  
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Table 4: SDS-PAGE analysis of fractions eluted out after affinity chromatography analysis to 
detect interactions between hPL kinase and rcSHMT 
Lane Fraction Result 
1 Column loaded with hPL 
kinase alone 
Washing No protein came out 
2 Elution Protein eluted out 
3 Column loaded with rcSHMT 
alone 
Washing rcSHMT got washed off from column 
4 Elution No protein was detected 
5 Column loaded with 1:1 
mixture of hPL kinase and 
rcSHMT 
Washing Some unbound rcSHMT got washed off 
6 Elution hPL kinase and rcSHMT got co-eluted 
7 Protein marker - 
 
From Figure 24 (lane 1 and lane 2), it can be seen that hPL kinase was successfully 
immobilized on NiNTA. On the other hand, rcSHMT did not show any non-specific binding to 
the NiNTA matrix, as the rcSHMT, loaded alone on the column, was found to be completely 
washed off the column with the washing buffer (lanes 3 and 4). When both the proteins, i.e. hPL 
kinase and rcSHMT were loaded together on column, it was found out that some of the rcSHMT 
got washed off, while the major fraction of rcSHMT, which remained bound to hPL kinase, was 
co-eluted along with hPL kinase. Similar experiment was conducted with lysozyme as a control, 
in place of rcSHMT. The result (not displayed here) showed no interaction between hPL kinase 
and lysozyme. This clearly suggests that PL kinase and SHMT interacts specifically with each 
other to form a complex. This further serves to support the idea of PLP channeling. The next step 
is the quantification of this protein-protein interaction, which we did by fluorescence 
polarization.  
49 
 
3.4.2: Fluorescence polarization (FP) to quantify protein-protein interactions: Our 
previous study using affinity chromatography showed that hPL kinase forms specific interaction 
with rcSHMT. Following the qualitative analysis of interaction by affinity chromatography, we 
used FP to quantify the interactions. For that we used E. coli PL kinase and several other PLP- 
dependent enzymes, including, E. coli L-threonine aldolase (eL-TA), E. coli aspartate 
aminotransferase (eAAT), E. coli serine hydroxymethyltransferase (eSHMT), rabbit cytosolic 
serine hydroxymethyltransferase (rcSHMT) and glycogen phosphorylase b (GlyPb) from rabbit 
muscle having molecular weights of 140 kDa, 90 kDa, 90.5 kDa, 220 kDa and 92 kDa 
respectively. All of these enzymes belong to fold-type I, except GlyPb which belongs to fold-
type V of B6 enzymes. The activity of PL kinase was not affected by the  tagging. The 
interactions of PL kinase with eSHMT, eL-TA, eAAT, rcSHMT and GlyPb were analyzed and 
the results are shown in Figure 25; 
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Figure 25: Fluorescence polarization titration; Change in fluorescence polarization intensity 
of FMI-PLK upon addition of increasing concentration of eSHMT (orange), eTA (light blue), 
eAAT (purple), rcSHMT (red) and Gly Pb (green) in 50 mM sodium HEPES, pH 7.55 containing 
150 mM KCl and 0.01% Triton. Controls LDH (  ) and lysozyme (+) were also run 
 
A simple 1:1 model provided the best fit to the interactions, resulting in the Kd values that 
range from 0.4-50 μM, as noted in Table 5. Similar experiments by Cheung et. al. with PL kinase 
and pig alanine aminotransferase or glutamate decarboxylase resulted in Kd values 5-15 μM.
35, 47
 
Interestingly, GlyPb binding was found to be the weakest. It may be due to the fact that it is the 
most abundant B6 enzyme in the body and the weak binding may act as control mechanism in 
order to prevent the GlyPb to out-compete all other apo B6 enzymes. In the experiments, we used 
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lysozyme and lactate dehydrogenase (LDH, dimer;~140 kDa) as controls to show that non-B6 
proteins did not have any significant binding to PL kinase. The variation in polarization values 
between different PLP-dependent enzymes might be due to the difference in molecular weights 
between them. 
Table 5: Affinity data for interactions of PL kinase with eSHMT, rcSHMT, eAAT, eTA and 
GlyPb 
Enzyme Affinity (Kd) 
eSHMT 8 ± 1.2 μM 
rcSHMT 8.4 ± 0.7 μM 
eAAT 0.4 ± 0.01 μM 
eTA 19 ± 2.8 μM 
GlyPb 56 ± 8 μM 
 
Fluorescence polarization data obtained for two different fold-types of PLP-dependent 
enzymes indicates that the binding between PL kinase and different PLP-dependent enzymes is 
specific. This data along with the binding data previously reported by Cheung et. al.
47 
provides a 
very strong support to the argument of PLP channeling from PL kinase to PLP-dependent 
enzymes.  
3.5 Conclusion: 
The data obtained from both affinity chromatography and fluorescence polarization 
clearly indicates that PL kinase binds with PLP-dependent enzymes. This data along with results 
of the PLP transfer experiments indicate that channeling of PLP from PL kinase to PLP- 
dependent enzymes is a strong possibility.  
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CHAPTER 4 
DETERMINE THE EFFECT OF  PL KINASE S261F MUTATION ON ENZYME 
ACTIVITY AND STRUCTURE 
 
4.1 Introduction: Several mutations on the genes coding for the B6 salvage enzymes, PL 
kinase and PNP oxidase have been reported. In many of the cases, these mutations were found to 
be deleterious to health, because they lead to decrease in the enzyme activity.
18-20, 63-65
 For PNP 
oxidase, many mutations have been linked to the fatal disorder, Neonatal epileptic 
encephalopathy.
19, 20, 63
 Decrease in co-factor (FMN) binding affinity is found to be the cause of 
the decrease in activity in one of the mutant, R229W.
19
 Similarly defective PL kinase has been 
reported in children suffering from autism.
64
 In this study, we determined the effect of a single 
nucleotide polymorphism, causing S261F mutation, on human PL kinase activity. Single 
nucleotide polymorphism, by definition, occurs in at-least 1% of the population.
74
 Hence, PL 
kinase, if affected by the S261F mutation, can lead to several disorders in large population 
carrying this SNP. This fact makes it essential to determine the effects of the mutation S261F on 
PL kinase’s function and structure. 
4.2 Materials: All culture media ingredients were purchased from Fischer Scientific 
(Pittsburgh, PA) or American Bioanalytical (Natick, MA). Nickel nitriloaceticacid (NiNTA) 
slurry was purchased from Qiagen (Valencia, CA). The QIAprep Spin Miniprep kit for plasmid 
isolation was purchased from Qiagen (Valencia, CA). The Quickchange Site-directed 
mutagenesis kit was purchased from Stratagene (La Jolla, CA).  All the substrates were 
purchased from Sigma (St. Louis, MO). Centrifugal filter devices were obtained from Milipore 
(Bedford, MA). 
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4.3 Methods: 
4.3.1 Site-directed mutagenesis: The recombinant plasmid containing gene pdxK, 
coding for PL kinase, inserted in pET 28a(+) was isolated by Qiagen’s QIAprep Spin Miniprep 
kit as per the protocol described by Qiagen. Polymerase chain reaction was carried out as per the 
protocol given by Stratagene. The following primers were used to carry out polymerase chain 
reaction;                                                                     
Forward primer: CAC CAC GTT CCA TTT GTG CCA GAA GAG 
Reverse primer: GTG GTG CAA GGT AAA CAC GGT CTT CTC 
The PCR product was transformed to E. coli XL-1 blue super-competent cells and 
transformants were grown on LB-agar media containing kanamycin (50 μg/mL) at 37°C. The 
following day, one colony was picked up and grown in 10 mL LB media, containing kanamycin 
(50 μg/mL), over night at 37°C. From this cell-culture, the plasmid, carrying the mutation, was 
isolated as described above. This plasmid was sent to VCU’s DNA core facility for sequencing 
to confirm the mutation. 
4.3.2 Optimization of expression condition for hPL kinase mutant (S261F): The 
mutant plasmid, after isolation from E. coli XL-1 blue supercompetent cells, was transformed to 
E. coli Rosetta (DE3) pLys cells for expression. The transformants were grown on LB-agar 
media containing kanamycin (50 μg/mL) and chloramphenicol (34 μg/mL), overnight at 37°C. 
The following day, one colony was picked up and grown in 10 mL LB-kanamycin-
chloramphenicol media, overnight at 37
°
C and used to inoculate two separate 50 mL LB-
kanamycin-chloramphenicol media. The cells were grown at 37
°
C until the OD600nm reached to 
0.8. The expression levels were analyzed at two different concentrations of β-
isopropylthiogalactopyranoside (IPTG), i.e. 50 μM and 0.5 mM. The cells, induced with 0.5 mM 
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IPTG, were grown for additional 5 hours at 37
°
C; while the cells, induced with 50 μM IPTG, 
were grown for 24 hours at 18
°
C. After the induction period, cells were harvested by 
centrifugation and ruptured separately by high-pressure homogenization using Avestin cell 
disruptor. For determination of expression levels, 1 mL of cell-lysate was taken from both the 
mixtures and centrifuged. The supernatants containing soluble fraction of protein were collected. 
The cell pellets, containing protein in insoluble fraction, were re-suspended using suitable buffer. 
All of these fractions, containing protein in soluble, as well as, in insoluble forms were analyzed 
by SDS-PAGE. 
4.3.3 Large scale expression and purification of mutant human PL kinase (S261F): 
The E. coli Rosetta (DE3) pLys cells containing the plasmid, carrying the mutation, were grown 
overnight at 37
°
C  with shaking in 200 mL LB-kanamycin-chloramphenicol media. It was used 
to inoculate 4 L LB-kanamycin-chloramphenicol media the following morning. Cells were 
grown until OD600nm reached to 0.8, induced with 50 μM β-isopropyl thiogalactopyranoside 
(IPTG), grown for additional 24 hours at 18
°
C and then harvested by centrifugation. Cell pellets 
were re-suspended in 150 mL cell-lysis buffer (50 mM NaH2PO4, pH 8 containing 300 mM NaCl 
and 10 mM imidazole). After re-suspension, the cells were ruptured by high-pressure 
homogenization using Avestin cell disruptor. Streptomycin sulfate was added to cell-lysate at 
concentration of 10 g/L to remove excess nucleic acids, which was then centrifuged to remove 
the precipitate and cell debris. The supernatant was decanted and loaded on NiNTA column, pre-
equilibrated with lysis buffer. The column was washed thoroughly with lysis buffer until 
OD280nm reached below 0.1, and further washed several times with the same buffer, containing 
higher concentrations of imidazole (10-75 mM). The enzyme was eluted from the column with 
50 mM monobasic sodium phosphate, pH 8.0, containing 300 mM NaCl, and 150 mM 
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imidazole. Fractions containing protein of >95% purity, as judged by SDS-PAGE, were pooled 
together and concentrated by precipitation with 60% ammonium sulfate. The protein pellets were 
stored at -20
°
C for further usage.   
4.3.4 Expression and purification of wild type PL kinase: The wild type PL kinase 
was expressed and purified as described in chapter 2 under section 2.3.1 
4.3.5 Activity analysis of purified PL kinase S261F: The activity analysis of purified 
mutant enzyme  was carried out as per the procedure described in chapter 2 under section 2.3.2 
Activity analysis of wild type enzyme was also carried out in the same manner to compare its 
activity with the mutant enzyme. Comparison was made at two different concentrations of both 
enzymes, i.e. hPL kinase S261F and hPL kinase wild type. 
4.3.6 Analysis of secondary structure: Secondary structural elements of wild-type and 
mutant enzyme were analyzed by recording circular dichroism (CD) spectra in a 0.5 cm cell at 
room temperature using Olis spectropolarimeter. The protein solutions were dialyzed against 20 
mM potassium phosphate buffer, pH 7.2 and diluted to 0.1 mg/mL before analysis.  All the 
spectra were blanked against buffer and recorded in range of 180 nm to 250 nm. The spectra 
were obtained in form of ellipticity vs. wave-length, which were normalized by converting 
ellipticity to Molar ellipticity by using equation 5. 
     
 
     
        
Where, Ɵ = molar ellipticity, Ɵ0 = observed ellipticity (in degrees), M = molecular weight, c = 
concentration, l = path-length of the cell and  
n = mean residual weight = 
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4.3.7 Tertiary structure analysis: Both wild-type and mutant enzymes, dialyzed against 
20 mM potassium phosphate buffer, pH 7.24, were analyzed by fluorescence spectroscopy. The 
measurements were done in a 1 cm cell using Shimadzu RF-5301 spectrofluorometer. The 
samples were excited at 295 nm and the emission-spectra were recorded between 300 to 400 nm, 
after blanking the spectrofluorometer against buffer. The slit-width was adjusted at 7.5 mm and 
all the measurements were done at room temperature.  
 4.3.8 Oligomerization state analysis: To check the oligomerization state, both mutant 
and wild-type enzymes were analyzed by native-PAGE. About 10 μL of each enzyme were 
mixed with 10 μL of native sample buffer and loaded on native gel. The gel was prepared 
without denaturants (SDS). It was run at 15 volts for about 2 hours. The gel was stained and, 
after destaining, analyzed for band positions of both the mutant and the wild-type enzyme. 
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4.4 Results and Discussion: 
4.4.1 Site-directed mutagenesis: The sequencing of isolated plasmid, carrying the 
mutation, was performed at DNA core facility at VCU. It was done by using standard T7 
promoter and T7 terminator primers. These primers were used for sequencing, as the vector 
pET28a(+) contained the T7-promoter and terminator sequences. The obtained sequence data 
was read in Applied Biosystem’s sequence viewer and it confirmed the mutation S261F. 
4.4.2: Optimization of expression condition for hPL kinase S261F: The main goal of 
expression condition optimization was to obtain the condition at which maximum amount of 
protein can be expressed to carry out further studies. The expression levels were analyzed at two 
different concentration of IPTG, which serves to induce protein production by bacteria. In one 
condition, IPTG was added to a concentration of 0.5 mM and cells were grown at 37
°
C, while in 
second condition, IPTG was added to a concentration of 50 μM and cells were grown at 18°C. 
The first condition is for fast induction, while the second is for slow induction. Slow induction, 
in some cases, may help in getting more soluble yields of protein due to more available folding 
opportunities during a slower process. In our case, both the conditions were analyzed before 
large-scale production. Figure 26 shows the result of analysis; 
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Figure 26: SDS-PAGE analysis for expression condition optimization of hPL kinase S261F; 
lane 1 corresponds to protein-marker, lane 2 and 3 correspond to protein in insoluble fractions 
for protein expressed at 37
°
C  and 18
°
C  respectively while lane 4 and 5 corresponds to the 
soluble fractions for 37
°
C  and 18
°
C , respectively 
 
As shown in Figure 26, the level of expression was slightly greater at 18
°
C, when low 
IPTG concentration was used. Therefore, the condition of low temperature with low IPTG 
concentration was used for large-scale protein-expression. 
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4.4.3 Large-scale expression and purification of human PL kinase S261F: The 
protein contained 6x-His tag at its N-terminal. Hence, purification, after cell-lysis, was 
performed by loading the cell-lysate on NiNTA column. Figure 27 shows the purification profile 
for hPL kinase S261F, and shows the enzyme purified to homogeneity, which was suitable for all 
further studies. 
 
 
 
 
 
 
 
 
Figure 27:Purification profile of hPL kinase S261F; SDS-PAGE analysis of fractions eluted 
from NiNTA column when the column was washed with 50 mM NaH2PO4 containing 300 mM 
NaCl and 150 mM Imidazole 
 
 
 
60 
 
4.4.4 Activity analysis: The enzymatic activity of the mutant and wild-type were studied 
and compared. Table 6 shows the result of that analysis; 
 
Table 6: Activity comparison of hPL kinase S261F and wild-type hPL kinase at two different 
concentrations of enzymes 
Enzyme concentration (mg/mL) 
Rate (min
-1
) 
Wild-type Mutant 
0.1 0.0275 ± 0.006 0.0235 ± 0.01 
0.2 0.0492 ± 0.015 0.0524 ± 0.012 
 
This analysis indicated that both the proteins were equally active and mutation had no 
effect on activity of protein. On the basis of this study, in-depth kinetic analysis was not pursued. 
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4.4.5 Secondary structure analysis: Circular Dichroism is a sensitive technique for 
characterization of protein structure. It can readily detect any change in protein structure.
83
 
Figure 28 shows the spectra for both proteins; 
 
Figure 28: Secondary structure comparison; CD spectra of both hPL kinase wild-type 
(blue) and hPL kinase S261F (red)  
 
The Far UV-CD spectra for both, wild-type and mutant enzymes were found to resemble 
each other, which suggest that the proteins have similar secondary structures; thus the mutation 
was not found to have any obvious effect on the secondary structure. 
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4.4.6 Tertiary structure analysis: Tertiary structures of the mutant, with the wild type 
as a control, were analyzed using fluorescence spectroscopy, by exciting the proteins at 295 nm 
and recording the emission spectra between 300-400 nm. This analysis employs the property of 
tryptophan residues, which have excitation maximum at 295 nm. Depending upon their local 
environment, characteristic emission spectrum with maximum between 308-355 nm is obtained. 
Any change in structure of protein and hence environments of tryptophan residues can change 
the spectrum also.
76 
Therefore, the comparison of spectra of wild-type and mutant hPL kinase 
can yield valuable information regarding the structural change, if any.  
 
  
Figure 29: Tertiary structure comparison; Fluorescence emission spectra for hPL kinase wild-
type (red) and hPL kinase S261F (blue) 
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Figure 29 shows the fluorescence spectra for both the hPL kinase wild-type and hPL 
kinase S261F, which indicates a slight decrease in the emission maximum as compared to wild-
type enzyme, but no shift of the maximum was noticed. The decrease in emission maximum 
could be due to a slight variation in protein concentrations because of difference in purity of both 
the enzymes. The result however shows that the tertiary structures of both the proteins are almost 
similar. The S261F mutation is probably not altering the structure and hence the function of hPL 
kinase. 
4.4.7 Oligomerization state analysis: The oligomerization state of the mutant with the 
wild type as a control was analyzed using Polyacrylamide gel electrophoresis (PAGE) under 
native conditions. The native PAGE separates the proteins depending on their molecular weights. 
Figure 30 shows native-PAGE analysis for both hPL kinase wild-type and hPL kinase S261F; 
 
 
 
 
 
 
 
Figure 30: Oligomerization state comparison; native PAGE analysis of hPL kinase 
wild-type and hPL kinase S261F 
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 Figure 30 clearly indicates that hPL kinase S261F is in identical oligomerization state as 
the wild-type enzyme and mutation is probably not affecting the quaternary structure as well. 
4.5 Conclusion: The effect of a Single Nucleotide Polymorphism in gene pdxK, coding 
for PL kinase S261F was analyzed. The mutant protein was successfully expressed and purified 
to homogeneity. This mutant was compared with the wild-type enzyme for its catalytic activity, 
as well as, secondary, tertiary and quaternary structures. In all aspects, it was found to be 
identical with wild-type enzyme. The results show that this SNP (S261F) in pdxK might not have 
any pathological implications. 
 
 
 
 
 
 
 
 
 
 
 
65 
 
CHAPTER 5 
DETERMINE THE EFFECT OF GINKGOTOXIN ON PL KINASE ACTIVITY AND 
STRUCTURE 
 
5.1 Introduction: For a very long time Ginkgo biloba has been considered as an 
important therapeutic agent. It is even considered sacred in some parts of the world because of its 
presumed therapeutic property. In mainland China and Japan, as well as several parts of the 
world, preparations from Ginkgo biloba are used to treat conditions such as, insufficiency of 
blood-flow, cerebral insufficiency, memory deficit, lack of concentration, depression, dizziness, 
tinnitus, vertigo and headaches, bronchial asthma, irritable bladder, cough and even alcohol 
abuse.
28
 Several clinical trials have also been reported for various preparations of G. biloba, but 
these studies have always resulted in controversial outcomes.
28
 Several reports for detailed 
analysis of G. biloba’s constituents have been published and they have identified an array of 
different constituents, including ginkgotoxin, also known as 4’-O-methylpyridoxine .29, 30 Apart 
from G. biloba, Ginkgotoxin is also found to be present in Albizzia species.
66
 Ginkgotoxin, as the 
name suggests, is a potent neurotoxin. Toxicity occurs due to over-dose of any medicinal 
preparation from G. biloba or by ingestion of seeds, which are used in diet in Japan, as well as in 
China.
30, 65
 Toxicities associated with ginkgotoxin are characterized by symptoms such as 
seizures, tonic/clonic convulsions, vomiting and impaired consciousness, which disappear with 
administration of PLP.
27, 29 
This led to the suggestion that ginkgotoxin may have inhibitory effect 
on PL kinase and/or PNP oxidase activities.  Several studies have confirmed ginkgotoxin’s 
inhibitory activity against the kinase, but not the oxidase.
27, 28, 77
 However, it has been suggested 
that the phosphorylated form of ginkgotoxin could inhibit the oxidase activity. This means that in 
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vivo phosphorylation of ginkgotoxin by the kinase may act on the oxidase to inhibit its activity. 
We have carried out in-depth kinetic analysis for ginkgotoxin inhibition of PL kinase and also 
used structural studies to understand the molecular basis of the inhibition. .  
5.2 Materials: 
The ginkgotoxin used in this study was synthesized by Dr. Danso-Danquah Richmond at 
the Institute for Structural Biology and Drug Discovery, VCU. 
5.3 Methods: 
5.3.1 Expression and purification of human PL kinase: Human PL kinase was 
expressed and purified as described previously in chapter 2 under section 2.3.1. The purified 
protein fractions after the NiNTA column were pooled together. Ammonium sulfate was added 
to 60% saturation to precipitate the protein. The protein pellet after ammonium sulfate was 
stored at -20
°
C for further use. 
5.3.2 Determination of kinetic parameters for inhibition of PL kinase by 
ginkgotoxin: The protein was dialyzed against 20 mM sodium BES buffer, pH 7. All the assays 
were done in a 1 cm thermo-stated cuvette using Agilent 8451 spectrophotometer. The assay for 
pyridoxal kinase activity was done as described previously in chapter 2 under section 2.3.2. The 
initial velocity data were recorded under the kinetic mode. For determination of kinetic 
parameters for inhibition, it was assumed that ginkgotoxin, due to structural similarity with PL, 
binds at the PL site. To confirm that and to determine the Ki for inhibition, three different 
concentrations (25 μM, 50 μM and 75 μM) of the drug ginkgotoxin were used and PL kinase was 
analyzed for activity at variable concentrations of PL (20-100 μM). MgATP was used at 
concentration of 1 mM. The initial velocity data were recorded in duplicate. The reciprocal rate 
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data were plotted against reciprocal of PL concentrations to obtain Lineweaver-Burk plot. The 
type of inhibition and kinetic parameter for the inhibition were determined from the plot. 
5.3.3 Crystallization of PL kinase along with ginkgotoxin: PL kinase was first 
dialyzed against 20 mM sodium BES buffer, pH 7 containing 200 mM NaCl and 5 mM β-
mercaptoethanol. The obtained protein solution was then concentrated to 25 mg/mL by using 
Centricon YM-10 centrifugal filter device. The concentrated protein solution was finally 
dialyzed against 20 mM sodium BES buffer, pH 7 containing 150 mM NaCl and 5 mM β-
mercaptoethanol. 
Wild-type PL kinase has previously been crystallized using 100 mM Tris-HCl, pH 8.0, 
and 52% 2-methyl-2,4-pentandiol (MPD) and 2.5 mM MgSO4. Therefore, all the co-
crystallization attempts of PL kinase (700 μM) with ginkgotoxin (2 mM) and MgATP (1 mM) 
were focused around this condition. MPD concentration was varied between 45-60%. Hanging-
drop method was used for the crystallization. X-ray quality crystals were obtained at the 
condition with 48% MPD.  
5.3.4 Data collection, integration and scaling: The crystal was cryo-protected in 
mother-liquor solution containing 1 mM MgATP and 2 mM ginkgotoxin and diffraction data 
collected at 100K using a Molecular Structure Corporation (MSC) X-Stream Cryogenic Crystal 
Cooler, a Rigaku IV ++ image plate detector, and a Rigaku MicroMax-007 X-Ray source 
(copper) fitted with MSC Varimax Confocal optics operating at 40 kV and 20 mA. Detector 
distance was set at 135 mm and exposure time was set at 2 minutes for each of the three frames, 
for which data was collected to assign unit cell parameters. After determining cell parameters, a 
total of 240 oscillation frames were collected, each at six minutes of exposure time. The data was 
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collected from φ 45° to 165° with 0.5° variations within each frame. Cell parameter determination 
and integration and scaling of data was done by d
*
trek provided in CrystalClear program 
package by Rigaku America Co. Integration of data was done by setting the resolution from 30 Å 
to 2.05 Å.  
  5.3.5 Structure determination: The diffraction intensity data was first converted to 
structure factor using the CCP4 suite of programs.
82 
The isomorphous structure of hPL kinase 
D235A mutant (pdb id 2FHX) was used as a starting model for structure determination. The 
bound MgATP, MPDs, waters and sulfates were omitted for refinements. All the refinements 
were done using CNS (Crystallographic and NMR systems) program.
78 
Rigid body refinement, 
conjugate gradient minimization, simulated annealing and B-factor refinements were performed. 
This led to identification of ginkgotoxin density at the PL site of both the subunits. MgATP 
density was also identified at both subunit active sites. The graphic programs, TOM
79
 and COOT 
(Crystallographic object-oriented tool-kit)
80
 were used for manual model adjustment as well as 
including the ginkgotoxin, MgATP, water, sulfate, MPD to the model. Refinements with 
intermittent model rebuilding have resulted in the current Rfree/Rwork of 28.3/25.4. Further 
refinement is ongoing. The data collection statistics and refinement parameters are shown in 
Table 7.   
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Table 7: Data collection statistics and refinement parameters for the structure of human PL 
kinase bound with ginkgotoxin  
Data collection statistics 
Space group  I222 
Unit cell a, b, c (Å) 92.75, 115.22, 169.55 
Resolution  range (Å) 28.81-2.10 (2.18-2.10) 
Total number of reflections 186720 
Number of unique reflections 49278 
Average redundancy 3.79 (3.84) 
% completeness 92.5 (92.3) 
Output <I/ Σ(I)> 16.5 (8.3) 
Rmerge
a
 0.075 (0.288) 
Refinement Statistics  
Rfree (%)
b
 28.3 
Rwork (%)
c
 25.4 
Average B (Å
2
)/No. of non-H atoms  
Protein 40.4 
Water 33 
MPD 72.8 
Anion 97.1 
Cation 39.6 
ATP 33.3 
Numbers in parentheses refer to the outer (highest) resolution shell
 
a 
Rmerge = Σ|I -〈I〉 |/Σ(I), where I is the observed intensity and 〈I〉 is the weighted mean of the  
reflection intensity 
b 
Rwork = Σ||Fo| -Fc|| / Σ|Fo|, where Fo and Fc are the observed and calculated structure factor
 
amplitudes, respectively 
d 
Rfree is the crystallographic Rwork calculated with 5 % of the data that were excluded from
 
the structure refinement 
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5.4 Results and Discussion: 
5.4.1 Determination of kinetic parameter for hPL kinase inhibition: Ginkgotoxin was 
tested for its inhibitory effects on hPL kinase. It was found to potently inhibit enzyme’s activity 
with Ki of 18 μM. The Lineweaver-Burk plot also suggests the inhibitory effect of ginkgotoxin to 
be competitive with the substrate PL. 
 
 
 
 
 
 
 
 
 
 
 
Figure 31: Lineweaver-Burk plot for characterization of Ginkgotoxin inhibition on hPL 
kinase 
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The study shows that Ginkgotoxin competitively inhibits PL binding, resulting in 
decrease in the metabolism of PL to PLP. Deficiency of PLP could potentially lead to disruption 
of the functions of several PLP-dependent enzyme activities causing neurotoxic effect. The 
competitive inhibition also suggests that ginkgotoxin is binding at the PL site of the enzyme.   
5.4.2 Structure of ginkgotoxin bound at PL kinase: Based on the kinetic studies that 
suggested ginkgotoxin may be binding at the PL binding site, we undertook structural studies to 
confirm this and also to explain on atomic level how this compound inhibits the kinase. Co- 
crystals of PL kinase-ginkgotoxin were obtained with a minor modification of a previously 
reported crystallization condition for the wild type enzyme.
6
 The structure was determined to a 
resolution of 2.1 Å. The current model contains 2 ginkgotoxin molecules, 2 ATP molecules, 2 
each of Na
+
 and Mg
2+
, 125 water, 6 sulfate and 6 MPD molecules. Both active sites have bound 
ginkgotoxin that closely superimpose on the substrate, PL.  Figure 32 shows the dimeric PL 
kinase structure with bound MgATP and ginkgotoxin.  The detailed PL kinase structure as well 
as the active site structure of PL kinase has previously been described.
6
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Figure 32: Dimeric structure of human PL kinase bound with ginkgotoxin and ATP; shown 
as spheres in yellow and red respectively. Monomer A and B are shown in green and blue 
respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Superposition of human PL kinase (unliganded) and human PL kinase 
(inhibitor- bound); shown in red and cyan respectively 
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Figure 33 shows superposition of human PL kinase (unliganded) and human PL kinase 
with ginkgotoxin. The rmsd for the superposition was 0.4 Å, and shows that binding of 
ginkgotoxin to PL kinase does not have a significant effect on the overall conformation of PL 
kinase dimeric structure. 
Each monomer of PL kinase has a unique active site that binds ATP, Mg
2+
 and Na
+
 
molecules, as well as a ginkgotoxin. The mode of ginkgotoxin binding is shown in Figure 34, 
which is similar to those described for previously published binary complexes of PL kinase with 
bound PL.
5
   
 
 
 
 
 
 
 
 
  
 
Figure 34: Binding of ginkgotoxin at the active-site of PL kinase 
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Figure 35: Superposition of human PL kinase (unliganded), sheep brain PL kinase (PL 
bound) and human PL kinase (inhibitor-bound) shown in red, yellow and cyan respectively 
 
Figure 35 also shows superposition of the active-sites of human PL kinase (unliganded), 
human PL kinase- ginkgotoxin complex, and sheep brain PL kinase-PL complex. The structural 
comparison shows that ginkgotoxin binds in a similar fashion as pyridoxal, without any gross 
change in the active site structure. As expected, the interactions associated with PL binding are 
conserved with ginkgotoxin binding. These include a hydrogen-bond interaction between O3 of 
ginkgotoxin and the main-chain nitrogen of Thr47; between N1 of ginkgotoxin and the –OH 
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group of Ser12; between the hydroxyl of the 5’–CH2OH and the carboxylate of Asp235. 
Theophylline and roscovitine, known inhibitors of PL kinase, are also known to inhibit PL kinase 
by binding to PL site of PL kinase, interacting with the same residues described above.
26 
There 
are two unique interactions, that are absent in the PL binding complex, which may serve to 
explain the high affinity of ginkgotoxin to PL kinase. The 4’-O-methyl substituent of 
ginkgotoxin, which is absent in PL, is found to be located between and forming hydrophobic 
interactions with the protein residues Tyr127 and Val231. Also, 5’–CH2OH of ginkgotoxin is 
involved in hydrogen-bond interaction with a nearby water molecule, which is held in position 
by hydrogen-bond interactions with the nearby Gln12 and Asp235. Although this water molecule 
is present in the unliganded PL kinase, it may possibly be playing structural role in ginkgotoxin 
binding.   
5.4 Conclusion: Detailed kinetic analysis of ginkgotoxin’s inhibition of PL kinase 
activity was carried out. It was found to inhibit PL kinase with a Ki of 18 μM, which is lower 
than the reported Km of 30 μM for PL. From the kinetic analysis it was found to be a competitive 
inhibitor of the substrate PL. The X-ray crystallographic structure of PL kinase-ginkgotoxin 
complex shows that ginkgotoxin bind at the PL site of each subunit without any gross change in 
protein conformation, but with additional protein interactions. This data gave an insight into the 
mechanism of ginkgotoxin inhibitory activity. The structural studies also suggest that the 5’–
CH2OH could easily be phsophorylated by the enzyme which can act on the oxidase to inhibits 
activity. 
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